Skip to content

    Ovarian Cancer Health Center

    Font Size
    A
    A
    A

    Pills Show Promise for Recurrent Ovarian Cancer

    Preliminary findings suggest this experimental treatment might slow disease

    WebMD News from HealthDay

    By Dennis Thompson

    HealthDay Reporter

    SATURDAY, May 31, 2014 (HealthDay News) -- A combination of two new pills may nearly double the length of survival for patients with recurrent ovarian cancer, according to preliminary clinical trial results.

    The therapy combines the drugs olaparib and cediranib. It provided nearly 18 months of progression-free survival on average, as opposed to nine months' survival with olaparib treatment alone, said Dr. Joyce Liu, a gynecologic oncologist at Dana-Farber Cancer Institute in Boston.

    Liu was scheduled to present the study findings Saturday at the American Society of Clinical Oncology meeting in Chicago.

    The results "compare favorably to what you'd see in chemotherapy," Liu said. This raises the possibility that this drug combination "might offer a non-chemotherapy alternative for the treatment of ovarian cancer," she said. Patients could swallow pills rather than go through intravenous chemo treatment.

    As many as four out of five women with aggressive ovarian cancer experience a relapse after chemotherapy, the researchers said. When the cancer returns, it is more likely to have spread to other parts of the body and to have developed resistance to chemotherapy.

    Because of this, researchers have been exploring alternate treatments for ovarian cancer that can overcome resistance to chemotherapy.

    Olaparib works by targeting an enzyme called PARP that repairs DNA damage in cells and, if inhibited, could cause cancer cells to die. Cediranib blocks the growth of blood vessels in a tumor, starving the cancer of the nutrition and oxygen it needs to survive.

    Both drugs are awaiting U.S. Food and Drug Administration approval, Liu said. And as with most studies presented at meetings, the findings should be considered preliminary until published in a peer-reviewed medical journal.

    The U.S. National Cancer Institute-funded trial involved 90 women with aggressive ovarian cancer that returned after chemotherapy. Participants were randomly assigned to receive treatment with olaparib alone or a combination of olaparib and cediranib. All had cancers that responded to platinum-based chemotherapy.

    Tumors shrank more dramatically during combination therapy -- 80 percent compared to 48 percent for patients who only received olaparib, the researchers found.

    Today on WebMD

    Ovarian cancer illustration
    What are the symptoms?
    doctory with x-ray
    Get to know the Symptoms.
     
    cancer cell
    HPV is the top cause. Find out more.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Integrative Medicine Cancer Quiz
    QUIZ
    Lifestyle Tips for Depression Slideshow
    SLIDESHOW
     
    Screening Tests for Women
    Slideshow
    Graphic of ovaries within reproductive system
    VIDEO
     
    Ovarian Cancer Marker
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Healthy meal with salmon
    Article